Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Novelion Therapeutics Inc | 24 |
| 2 | Pharmacia and Upjohn Co | 23 |
| 3 | Bausch Health Companies Inc | 16 |
| 4 | BASF SE | 9 |
| 5 | Baxter International Inc | 7 |
| 6 | Novartis AG | 7 |
| 7 | Firmenich Inc | 6 |
| 8 | General Hospital Corp | 6 |
| 9 | United States Department of Health and Human Services | 6 |
| 10 | ADIR SARL | 5 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 123 |
| 2 | A61P | Therapeutic activity (drug indications) | 119 |
| 3 | C07D | Heterocyclic compounds | 95 |
| 4 | A61N | 26 | |
| 5 | C07K | Peptides | 23 |
| 6 | A61F | 12 | |
| 7 | A61Q | Cosmetics, personal care | 12 |
| 8 | A23V | Foods, foodstuffs - indexing scheme | 10 |
| 9 | C07F | Organometallic compounds | 10 |
| 10 | A23L | Foods and beverages (general) | 9 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Method for extraction and separation of visnagin | 2012 | SHANXI JIAHE PLANT CHEMICAL CO., LTD. | 1 |
| Method for extraction and separation of visnagin | 2015 | SHAANXI JIAHE PHYTOCHEM CO.,LTD. | 0 |
| CHEMICAL STRUCTURE TRANSFORMATION OF VISNAGIN FOR PREVENTION OR TREATMENT OF DISEASES IN CENTRAL NERVOUS SYSTEM | 2011 | INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY | 0 |
| Method for the preparation of visnagin from chellol and new compositions of matter | 1953 | GEISSMAN THEODORE A | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Bioactive Compounds and Antitumor Agents | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Lucia Bovalini | University of Siena | 5 |
| 2 | Veronika Butterweck | University of Florida | 5 |
| 3 | P. Martelli | University of Siena | 4 |
| 4 | Bruce S. Edwards | University of New Mexico | 3 |
| 5 | J. B. Hudson | University of British Columbia | 3 |
| 6 | Keriman Günaydın | Mustafa Kemal University | 3 |
| 7 | Larry A. Sklar | University of New Mexico | 3 |
| 8 | Matthew Saunders | University of New Mexico | 3 |
| 9 | Neslihan Beyazıt | Mustafa Kemal University | 3 |
| 10 | Pattaraporn Vanachayangkul | University of Florida | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase | 2014 | 138 | Mitochondrial Function and Pathology |
| A new steroid glycoside and furochromones from <b> <i>Cyperus rotundus</i> </b> L. | 2007 | 84 | Botany and Plant Ecology Studies |
| Prevention of renal crystal deposition by an extract of Ammi visnaga L. and its constituents khellin and visnagin in hyperoxaluric rats | 2010 | 82 | Kidney Stones and Urolithiasis Treatments |
| Synthesis of New Visnagen and Khellin Furochromone Pyrimidine Derivatives and Their Anti-Inflammatory and Analgesic Activity | 2011 | 81 | Synthesis and biological activity |
| Visnagin attenuates acute pancreatitis via Nrf2/NFκB pathway and abrogates associated multiple organ dysfunction | 2019 | 76 | Pancreatitis Pathology and Treatment |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and structure of Visnagin?
Which organizations hold the most patents related to Visnagin?
What are the main patent classifications for Visnagin-related inventions?
What notable research has been published on Visnagin's biological effects?
Who are the leading researchers publishing on Visnagin?